COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of ACCESS PHARMACEUTICALS, INC.Warrant Agreement • June 16th, 2006 • Access Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS IS TO CERTIFY THAT or registered assigns (the “Holder”), is entitled, during the Exercise Period (as hereinafter defined), to purchase from Access Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Warrant Stock (as hereinafter defined and subject to adjustment as provided herein), in whole or in part, at a purchase price of $0.264 per share, all on and subject to the terms and conditions hereinafter set forth.
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 16th, 2006 • Access Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Agreement is being entered into pursuant to the Convertible Note and Warrant Purchase Agreement, dated as of the date hereof, by and among the Company and the Purchasers (the “Purchase Agreement”).
AMENDMENT TO RIGHTS AGREEMENTRights Agreement • June 16th, 2006 • Access Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Amendment to Rights Agreement, dated as of February 16, 2006 (the “Amendment”), is by and between Access Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, a New York corporation (the “Rights Agent”), amending certain provisions of the Rights Agreement, dated as of October 31, 2001 (as amended and in effect from time to time, including, without limitation, by that certain Amendment to Rights Agreement, dated as of October 31, 2005, the “Agreement”), by and between the Company and the Rights Agent. Terms not otherwise defined herein which are defined in the Agreement shall have the same respective meanings herein as therein.
SECURITY AGREEMENTSecurity Agreement • June 16th, 2006 • Access Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SECURITY AGREEMENT is made as of February 16, 2006 between the lenders listed on the signature page hereto (hereinafter, collectively, the “Secured Parties”) and Access Pharmaceuticals, Inc., a Delaware corporation with its chief executive office located at 2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207, Attention: President (the “Debtor”).
